Clinical experience with the combined use of recombinant interleukin‐2 (IL2) and interferon alfa‐2a (IFNα) in metastatic melanoma

Interleukin-2: Inception, Impact, and Implications

1988 • 2,166 citations

Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

1989 • 1,003 citations

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

1989 • 383 citations

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

1989 • 240 citations

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1988 • 200 citations

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

1988 • 153 citations

In vivo anti‐tumor activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells

1987 • 146 citations

In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.

1988 • 131 citations

Combination Immunotherapy for Cancer:Synergistic Antitumor Interactions of Interleukin-2, Alfa Interferon, and Tumor-Infiltrating Lymphocytes

1988 • 128 citations

Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.

1989 • 57 citations

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.

1989 • 56 citations

Partial reversion of the transformed phenotype of murine sarcoma virus-transformed cells in the presence of interferon: A possible mechanism for the anti-tumour effect of interferon

1981 • 47 citations

Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies

1989 • 46 citations

Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.

1986 • 37 citations

Characteristics and uses of IL-2 in immunotherapy

1989 • 3 citations